Preferred Label : selinexor;
MeSH note : inhibits karyopherin XPO1;
CISMeF synonym : KPT-330;
UNII : 31TZ62FO8F;
Origin ID : C585161;
UMLS CUI : C3852671;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3427490/fr/nexpovio-selinexor-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing precisely selinexor 20 milligram/1 each conventional release oral
tablet (clinical drug)
administration, oral
selinexor
antineoplastic agents
antineoplastic combined chemotherapy protocols
adult
Dexamethasone/Selinexor Regimen
Triple-Class Refractory Multiple Myeloma
evaluation of the transparency committee
selinexor
multiple myeloma
---
https://ansm.sante.fr/tableau-acces-derogatoire/selinexor
2023
false
false
false
France
French
drug information
multiple myeloma
selinexor
selinexor
Product containing precisely selinexor 20 milligram/1 each conventional release oral
tablet (clinical drug)
---
https://www.has-sante.fr/jcms/p_3433395/fr/nexpovio-selinexor-myelome-multiple
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
multiple myeloma
Product containing precisely selinexor 20 milligram/1 each conventional release oral
tablet (clinical drug)
administration, oral
selinexor
selinexor
antineoplastic combined chemotherapy protocols
dexamethasone
Dexamethasone/Selinexor Regimen
Refractory Multiple Myeloma
adult
antineoplastic agents
drug resistance, neoplasm
---
https://www.cadth.ca/fr/selinexor
2022
false
false
false
Canada
French
canada
drug information
Xpovio
selinexor
antineoplastic combined chemotherapy protocols
multiple myeloma
Bortezomib/Dexamethasone/Selinexor Regimen
selinexor
adult
---
https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
selinexor
selinexor
drug approval
europe
selinexor
antineoplastic agents
antineoplastic agents
multiple myeloma
antineoplastic combined chemotherapy protocols
dexamethasone
Bortezomib/Dexamethasone/Selinexor Regimen
adult
aged
Refractory Multiple Myeloma
administration, oral
Exportin 1 Protein
drug monitoring
Female of Childbearing Potential
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely selinexor 20 milligram/1 each conventional release oral
tablet (clinical drug)
Bortezomib
hydrazines
triazoles
hydrazines
triazoles
receptors, cytoplasmic and nuclear
karyopherins
---